Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12337359 | 0.91 | MEN1 (0.33) | DHFRMEN1KMT2AATMPOLB | |
| SCHEMBL12313476 | 0.83 | KMT2A (0.34) | DHFRMEN1KMT2AATMKDM4E | |
| SCHEMBL12337358 | 0.81 | S1PR1 (0.39) | DHFRMEN1KMT2AATMPOLB | |
| SCHEMBL10039488 | 0.79 | TP53 (0.35) | DHFRMEN1KMT2AL3MBTL1PPARG | |
| SCHEMBL10039481 | 0.67 | RXRA (0.35) | DHFR | |
| SCHEMBL20906691 | 0.67 | LTA4H (0.35) | TP53PLA2G2A | |
| SCHEMBL23261736 | 0.66 | TP53 (0.41) | L3MBTL1TP53 | |
| SCHEMBL14291457 | 0.66 | TSHR (0.49) | MEN1KMT2AL3MBTL1POLBFFAR4 | |
| SCHEMBL11585186 | 0.65 | TP53 (0.43) | MEN1KMT2AKDM4ETP53 | |
| SCHEMBL7637040 | 0.64 | LMNA (0.49) | MEN1KMT2APOLBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263794-B2 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | ELOVL3, LIPA, FFAR2 | DHFR 3897/4885MEN1 4052/4885KMT2A 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.